HeraMED Ltd. (1I4) AI Stock Analysis

0 Followers

HeraMED Ltd.

(Frankfurt:1I4)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Improved Gross MarginThe move from negative gross margins in 2020–2022 to roughly 60% in 2023–2024 shows that HeraMED’s offerings can generate positive gross profit. If maintained, this improvement provides a stronger base for covering operating costs and converting revenue growth into better earnings over time.

Negative Factors

Revenue ContractionRecent revenue contraction and historical volatility indicate that commercial expansion has not yet become dependable. A shrinking or inconsistent top line limits operating leverage, makes fixed costs harder to absorb, and reduces the company’s ability to fund product development and scale from internally generated growth.

HeraMED Ltd. (1I4) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 26.46M
Dividend Yield: ―
Average Volume (3M): 37.81K
Price to Earnings (P/E): -10.9
Beta (1Y): 1.01
Revenue Growth: -55.21%
EPS Growth: 41.94%
Country: Germany
Employees: 6
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

HeraMED Ltd. Business Overview & Revenue Model

Company Description

HeraMED Limited and its associated entities are dedicated to the design, production, and sale of at-home fetal heart rate monitors and comprehensive pregnancy monitoring systems. These solutions are offered to consumers throughout Australia, Europe,...

HeraMED Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:1I4 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:RMD	84Outperform	AUD 48.08B	21.70	25.14%	1.07%	1.54%	4.43%
AU:CMP	54Neutral	AUD 47.94M	218.18	0.93%	―	18.54%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:UCM	43Neutral	AUD 3.12M	-1.56	-1788.57%	―	-52.22%	44.79%
AU:AT1	40Underperform	AUD 10.83M	-3.10	-48.97%	―	40.65%	45.45%
AU:IPD	39Underperform	AUD 14.66M	-0.34	-259.31%	―	14.85%	-1.74%

* Healthcare Sector Average

Performance Comparison

DE:1I4 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:1I4	HeraMED Ltd.	0.02	-0.01	-25.93%
AU:CMP	Compumedics Limited	0.25	-0.09	-27.54%
AU:IPD	Impedimed Limited	0.01	-0.03	-64.10%
AU:UCM	Uscom Limited	0.01	0.00	0.00%
AU:AT1	Atomo Diagnostics Ltd.	0.01	-0.02	-56.67%
AU:RMD	Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh	33.87	-4.07	-10.73%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

HeraMED Ltd. AI Stock Analysis